Projects

RNDr. Jana Jakubíková, PhD.

International

Finished
  • INNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER
    Program: Other
    Duration: 1. 4. 2018 – 31. 12. 2021
  • Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy
    Program: ERANET
    Duration: 1. 7. 2016 – 31. 7. 2020

National

Current
  • Bacterial Lon protease as an emerging tool for multiple myeloma treatment
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Novel Drug Approaches Targeting Cancer Stem-like Cells in Multiple Myeloma Pathogenesis
    Program:
    Duration: 1. 8. 2024 – 30. 6. 2026
  • Modulation of CXCR4/CXCL12 axis by the anti-myeloma activity of CXCR4 antagonist WZ811
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2025
Finished
  • Cancer immunoediting in multiple myeloma: immune checkpoints and clinical significance
    Program: SRDA
    Duration: 1. 8. 2021 – 30. 6. 2025
  • Preparation of new antibiotics and antitumor agents by manipulations of secondary metabolite genes and synthetic biology methods
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Harnessing the immunological mechanisms in various subtypes of B cell lymphoma
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Anti-myeloma activity by composite realgar nanomaterials and its mechanism in vitro and in vivo
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2022
  • Development of novel diagnostic and predictive high-dimensional immunophenotyping tool for hematological malignancies
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • Assessment of immune checkpoints in B cell malignancies
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2022
  • Tumor heterogeneity in multiple myeloma: evolution and clinical relevance
    Program: SRDA
    Duration: 1. 7. 2017 – 31. 12. 2021
  • Mechanism of anti-tumor activity of realgar nanoparticles and its synergism with anti-myeloma agents
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2019
  • Clonal dynamics of multiple myeloma
    Program: SASPRO
    Duration: 1. 9. 2015 – 31. 8. 2018
  • Role of microenvironment and B-cell immunity in the spontaneous regression of MM patients undergoing hight dose therapy and autologous stem cell transplantation
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 6. 2017
  • Anticancer effects of isothiocyanates and their combination with other therapeutic approaches.
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Effect of natural compounds isothiocyanates (ITCs) on cellular mechanisms and markers associated with aggressive phenotype and treatment responsiveness in breast and ovarian cancer
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Cytogenetic monitoring of the responses of the patients with carcinoma theradiotherapy succes
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Chemotherapy, multidrug resistance (MDR) its modulation and relationship of these events to programmed cell death (apoptosis) in human tumor cells
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Epithelial-mesenchymal transition in the model of breast carcinoma stem cells in vitro
    Program: SRDA
    Duration: 1. 3. 2006 – 1. 3. 2009
  • Monitoring of immunological parameters of multiple myeloma patients during course of Biobran consumption
    Program: Other projects
    Duration: 1. 1. 2005 – 31. 12. 2008
  • Study of new prognostic markers of therapeutical approaches in gynecologic malignancies: factors and pathways influencing course of the disease and antitumour immunity
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees